Paul Hammerness

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02138, USA
    J Pediatr 162:22-7.e2. 2013
  2. ncbi Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot study
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, 02138, USA
    CNS Neurosci Ther 18:34-40. 2012
  3. ncbi Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02138, USA
    J Pediatr 155:84-9, 89.e1. 2009
  4. ncbi Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations
    Paul G Hammerness
    Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, and Harvard Medical School, USA
    J Am Acad Child Adolesc Psychiatry 50:978-90. 2011
  5. ncbi Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications
    Paul G Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital and Harvard University Medical School, Cambridge, MA 02138, USA
    Curr Psychiatry Rep 13:357-63. 2011
  6. ncbi Does ADHD moderate the manifestation of anxiety disorders in children?
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA 02138, USA
    Eur Child Adolesc Psychiatry 19:107-12. 2010
  7. ncbi Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Eur Child Adolesc Psychiatry 18:493-8. 2009
  8. ncbi Update on adult attention-deficit/hyperactivity disorder
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, 185 Alewife Brook Parkway, Suite 2000, Cambridge, MA 02138, USA
    Curr Neurol Neurosci Rep 8:484-9. 2008
  9. ncbi Characterizing non-OCD anxiety disorders in psychiatrically referred children and adolescents
    Paul Hammerness
    Massachusetts General Hospital, Pediatric Psychopharmacology Unit, Boston, MA 02138, United States
    J Affect Disord 105:213-9. 2008
  10. ncbi An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics
    Paul Hammerness
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston Massachusetts, USA
    J Child Adolesc Psychopharmacol 19:493-9. 2009

Detail Information

Publications39

  1. ncbi Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02138, USA
    J Pediatr 162:22-7.e2. 2013
    ..Although attention-deficit hyperactivity disorder (ADHD) is a well-known risk factor for cigarette smoking, prospective studies aimed at reducing smoking risk in this population are critically needed...
  2. ncbi Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot study
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, 02138, USA
    CNS Neurosci Ther 18:34-40. 2012
    ....
  3. ncbi Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02138, USA
    J Pediatr 155:84-9, 89.e1. 2009
    ..To examine the effects of high doses of extended-release methylphenidate (OROS MPH) on cardiovascular variables in adolescents with attention deficit hyperactivity disorder (ADHD)...
  4. ncbi Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations
    Paul G Hammerness
    Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, and Harvard Medical School, USA
    J Am Acad Child Adolesc Psychiatry 50:978-90. 2011
    ..This review provides an update on the cardiovascular impact of therapeutic stimulant-class medication for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)...
  5. ncbi Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications
    Paul G Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital and Harvard University Medical School, Cambridge, MA 02138, USA
    Curr Psychiatry Rep 13:357-63. 2011
    ..Further research is indicated to delineate clinical and functional outcomes for adults with ADHD, as well as long-term safety of medication treatment...
  6. ncbi Does ADHD moderate the manifestation of anxiety disorders in children?
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA 02138, USA
    Eur Child Adolesc Psychiatry 19:107-12. 2010
    ..ADHD had a limited impact on the manifestation of anxiety disorder in children suggesting that ADHD and anxiety disorders are independently expressed...
  7. ncbi Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Eur Child Adolesc Psychiatry 18:493-8. 2009
    ..In conclusion, atomoxetine was generally well tolerated; 85% of subjects completed the trial. Atomoxetine was effective and well tolerated in a 6-week open study of ADHD youth with a prior history of stimulant treatment...
  8. ncbi Update on adult attention-deficit/hyperactivity disorder
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, 185 Alewife Brook Parkway, Suite 2000, Cambridge, MA 02138, USA
    Curr Neurol Neurosci Rep 8:484-9. 2008
    ....
  9. ncbi Characterizing non-OCD anxiety disorders in psychiatrically referred children and adolescents
    Paul Hammerness
    Massachusetts General Hospital, Pediatric Psychopharmacology Unit, Boston, MA 02138, United States
    J Affect Disord 105:213-9. 2008
    ..To characterize childhood and adolescent anxiety disorders in a psychiatric clinic...
  10. ncbi An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics
    Paul Hammerness
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Harvard Medical School, Boston Massachusetts, USA
    J Child Adolesc Psychopharmacol 19:493-9. 2009
    ..The aim of this study was to evaluate the tolerability of adding OROS methylphenidate (MPH) to children who are partial responders to atomoxetine (ATMX) in the treatment of attention-deficit/hyperactivity disorder (ADHD)...
  11. ncbi A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder
    Gagan Joshi
    Pediatric Psychopharmacology Research Department, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Child Adolesc Psychopharmacol 20:7-14. 2010
    ..The aim of this study was to evaluate the safety and efficacy of extended release carbamazepine (CBZ-ER) monotherapy in the treatment of pediatric bipolar disorder (BD)...
  12. ncbi Is oppositional defiant disorder a meaningful diagnosis in adults? Results from a large sample of adults with ADHD
    Theresa Harpold
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Nerv Ment Dis 195:601-5. 2007
    ..A better understanding of the course, phenomenology, and clinical significance of ODD in adults is needed to better understand therapeutic approaches for this disorder...
  13. ncbi A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology at the Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Psychiatry 59:829-35. 2006
    ..The objective of this study was to evaluate the safety and efficacy of once-daily OROS methylphenidate (MPH) in the treatment of adults with DSM-IV attention-deficit/hyperactivity disorder (ADHD)...
  14. ncbi An open-label trial of OROS methylphenidate in adults with late-onset ADHD
    Joseph Biederman
    Joint Program, Pediatric Psychopharmacology Research Office, Massachusetts General Hospital, Boston, MA 02114, USA
    CNS Spectr 11:390-6. 2006
    ..We hypothesized that treatment with oral release osmotic system (OROS) methylphenidate (MPH) will be safe and efficacious for the treatment of adults with late-onset ADHD...
  15. ncbi A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study
    Joseph Biederman
    Clinical and Research Program, Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 26:163-6. 2006
    ..Because of its cholinergic nicotinic mechanism of action, galantamine HBr was hypothesized to have therapeutic activity in the treatment of attention-deficit/hyperactivity disorder (ADHD)...
  16. ncbi A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate
    Thomas J Spencer
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Atten Disord 15:286-94. 2011
    ..The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH)...
  17. ncbi A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA, USA
    CNS Neurosci Ther 16:91-102. 2010
    ..To evaluate the safety and efficacy of lamotrigine monotherapy as an acute treatment of bipolar mood elevation in children with bipolar spectrum disorders...
  18. ncbi A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder
    Gagan Joshi
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Affect Disord 136:1143-53. 2012
    ..This study evaluates the response to quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder (BSD)...
  19. ncbi The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the manchester driving behavior questionnaire
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Adolesc Health 51:601-7. 2012
    ..The focus of this report is on assessing the impact of lisdexamfetamine dimesylate (LDX) on driving behaviors in young adults with ADHD using a validated driving behavior questionnaire...
  20. ncbi A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 30:549-53. 2010
    ..More work is needed to be conducted with larger samples being followed to study completion to better understand the long-lasting impact of pharmacotherapy for adult attention-deficit/hyperactivity disorder...
  21. ncbi An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder
    Joseph Biederman
    Joint Program in Pediatric Psychopharmacology Research Office, Massachusetts General Hospital, Boston, MA 02114, USA
    CNS Spectr 12:683-9. 2007
    ..Aripiprazole is a novel second-generation antipsychotic approved for the treatment of bipolar disorder in adults but there is no systematic data available in pediatric bipolar disorder...
  22. ncbi Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study
    Craig Surman
    Massachusetts General Hospital, Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, and Harvard Medical School, Boston, MA, USA
    CNS Neurosci Ther 16:6-12. 2010
    ..These open-label results suggest that ATX may be safe and effective in the treatment of adults meeting criteria for ADHD-NOS and support the need for further controlled clinical trials of ATX in this population...
  23. ncbi Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
    Joseph Biederman
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Psychiatry 7:49. 2007
    ..The main aim of this study was to compare the safety and efficacy of IR MPH administered three times daily to those of once daily OROS-MPH...
  24. ncbi An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Child Adolesc Psychopharmacol 19:485-92. 2009
    ..This study evaluated the effectiveness of adding OROS methylphenidate (MPH) to children who are partial responders to atomoxetine (ATMX) in the treatment of attention-deficit/hyperactivity disorder (ADHD)...
  25. ncbi An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder
    Timothy E Wilens
    Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Biol Psychiatry 54:9-16. 2003
    ..Further controlled trials are warranted...
  26. ncbi The familial association between cigarette smoking and ADHD: a study of clinically referred girls with and without ADHD, and their families
    Michael C Monuteaux
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Nicotine Tob Res 10:1549-58. 2008
    ..These findings support the hypothesis that the combination of ADHD and smoking comprises an etiologically distinct familial subtype of ADHD in girls...
  27. ncbi Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder
    Gagan Joshi
    Pediatric Psychopharmacology Research Department, Massachusetts General Hospital, USA
    CNS Neurosci Ther 18:28-33. 2012
    ..To assess the impact of comorbid autism spectrum disorders (ASD) on the response to second-generation antipsychotics (SGA) in pediatric bipolar disorder (BPD)...
  28. ncbi A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Massachusetts General Hospital, 55 Fruit St, YAW 6900, Boston, MA 02114, USA
    J Clin Psychiatry 71:548-56. 2010
    ..Our aim was to examine the effects of the methylphenidate transdermal system (MTS) on before-school ADHD symptoms and functioning in children with ADHD...
  29. ncbi Cigarette smoking as a risk factor for other substance misuse: 10-year study of individuals with and without attention-deficit hyperactivity disorder
    Joseph Biederman
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Br J Psychiatry 201:207-14. 2012
    ..We previously documented that cigarette smoking is a risk factor for subsequent alcohol and drug misuse and dependence in adolescent girls with attention-deficit hyperactivity disorder (ADHD)...
  30. ncbi The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm
    Joseph Biederman
    Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA 02114 3139, USA
    J Psychiatr Res 46:484-91. 2012
    ..placebo. LDX treatment was associated with significantly faster reaction times and a lower rate of simulated driving collisions than placebo. These results suggest that LDX may reduce driving risks in young adults with ADHD...
  31. ncbi Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children
    Joseph Biederman
    Pediatric Psychopharmacology Research Department, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Psychiatry 58:589-94. 2005
    ..To evaluate short-term safety and efficacy of atypical antipsychotics in a single-site, prospective, open-label, 8-week study of risperidone and olanzapine monotherapy in preschoolers with bipolar disorder (BPD)...
  32. ncbi Reexamining the familial association between asthma and ADHD in girls
    Paul Hammerness
    Massachusetts General Hospital and Harvard Medical School, MA 02114, USA
    J Atten Disord 8:136-43. 2005
    ..These findings further support the conclusion that ADHD symptoms should not be dismissed as part of asthma symptomatology or a consequence of its treatment...
  33. ncbi Risperidone treatment for ADHD in children and adolescents with bipolar disorder
    Joseph Biederman
    Pediatric Psychopharmacology Research Department, Massachusetts General Hospital Boston, MA, USA
    Neuropsychiatr Dis Treat 4:203-7. 2008
    ..The objective of this study was to estimate improvement in ADHD symptoms in children with bipolar disorder...
  34. ncbi A controlled study of a simulated workplace laboratory for adults with attention deficit hyperactivity disorder
    Ronna Fried
    Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States
    Psychiatry Res 200:949-56. 2012
    ....
  35. ncbi Examining the nature of the association between attention-deficit hyperactivity disorder and nicotine dependence: a familial risk analysis
    Joseph Biederman
    Massachusetts General Hospital, Boston, MA, USA
    Can J Psychiatry 58:177-83. 2013
    ..To use familial risk analysis to examine the association between attention-deficit hyperactivity disorder (ADHD) and nicotine dependence (ND)...
  36. ncbi Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
    Paul Hammerness
    Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USA
    Neuropsychiatr Dis Treat 5:215-26. 2009
    ....
  37. ncbi Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex
    Constance M Moore
    Brain Imaging Center, McLean Hospital, Belmont, MA 02478, USA
    J Affect Disord 99:19-25. 2007
    ..In this study, we hypothesized that the children with BPD in need of treatment would have lower Glx/Cr compared with the children with BPD being stably treated with risperidone...
  38. ncbi Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study
    Constance M Moore
    Brain Imaging Center, McLean Hospital, Belmont, MA 02478, USA
    Am J Psychiatry 163:316-8. 2006
    ....
  39. ncbi Linezolid: MAOI activity and potential drug interactions
    Paul Hammerness
    Psychosomatics 43:248-9. 2002